Inhibition of ovarian function using a triphasic combination with gestodene

Rozenbaum, H.

Revue Francaise de Gynecologie et d'Obstetrique 83(6): 449-452


ISSN/ISBN: 0035-290X
PMID: 3406638
Document Number: 366185
The estradiol (E2) and progesterone levels of 10 healthy women aged 20- 40 were measured during 6 months of use of a triphasic oral contraceptive (OC) containing gestodene to assess the degree of inhibition of follicular activity and ovulation. The OC contained 30 mcg of ethinyl estradiol (EE) and 50 of gestodene for 6 days, 40 mcg of EE and 70 of gestodene for 5 days, and 30 mcg EE and 100 of gestodene for 10 days. Cholesterol and triglyceride levels and side effects were also prospectively studied. Samples were taken during a control cycle and during study cycles 1, 3, and 6. Serum progesterone levels ranging from 6-26 ng/ml demonstrated ovulation in 9 of the 10 women during the control cycle. Luteal insufficiency was observed in 1 case. Serum estradiol levels were normal in all cases during the control cycle. Estradiol levels were lower than during a normal follicular phase beginning in the 1st week of treatment and remained very low for the duration of treatment, including during the week without pills. Estradiol levels were between 10-60 pg/ml. Serum progesterone levels were at the limit of detectability, rarely reaching 1 ng/ml. Levels of cholesterol, apolipoprotein B, and hemoglobin remained stable over the course of the study. HDL cholesterol and apolipoprotein A levels increased slightly but not significantly. Triglyceride levels increased slightly at 6 months. Overall clinical tolerance was good. There was 1 case of metrorrhagia and spotting. 2 cases of breast tenderness were noted. Variations in weight and blood pressure were minimal. In conclusion, the formulation provided a profound and constant inhibition of ovulation and ovarian steroidogenesis and a nearly neutral metabolic effect.

Document emailed within 1 workday
Secure & encrypted payments